IDYA

IDYA

USD

IDEAYA Biosciences Inc. Common Stock

$30.240+0.800 (2.717%)

实时价格

Healthcare
生物技术
美国

价格图表

Loading Chart...

关键指标

市场指标
公司基本面
交易统计

市场指标

开盘价

$29.440

最高价

$30.450

最低价

$28.840

成交量

0.19M

公司基本面

市值

2.7B

所属行业

生物技术

国家/地区

United States

交易统计

平均成交量

1.21M

交易所

NMS

货币

USD

52周价格范围

最低价 $13.45当前价 $30.240最高价 $33.64

相关新闻

PR Newswire

IDEAYA Biosciences Reports Third Quarter 2025 Financial Results and Provides Business Update

IDEAYA Biosciences, Inc. (Nasdaq: IDYA), a leading precision medicine oncology company, provided a business update and announced financial results...

查看更多
IDEAYA Biosciences Reports Third Quarter 2025 Financial Results and Provides Business Update
PR Newswire

IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics,...

查看更多
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
PR Newswire

IDEAYA Biosciences to Participate in Upcoming November 2025 Investor Relations Events

IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics,...

查看更多
IDEAYA Biosciences to Participate in Upcoming November 2025 Investor Relations Events
Analyst Upgrades

JP Morgan Maintains Overweight on IDEAYA Biosciences, Raises Price Target to $79

JP Morgan analyst Anupam Rama maintains IDEAYA Biosciences with a Overweight and raises the price target from $74 to $79.

查看更多
JP Morgan Maintains Overweight on IDEAYA Biosciences, Raises Price Target to $79
Analyst Upgrades

Goldman Sachs Maintains Neutral on IDEAYA Biosciences, Raises Price Target to $30

Goldman Sachs analyst Corinne Jenkins maintains IDEAYA Biosciences with a Neutral and raises the price target from $27 to $30.

查看更多
Goldman Sachs Maintains Neutral on IDEAYA Biosciences, Raises Price Target to $30
Analyst Upgrades

RBC Capital Maintains Outperform on IDEAYA Biosciences, Raises Price Target to $41

RBC Capital analyst Leonid Timashev maintains IDEAYA Biosciences with a Outperform and raises the price target from $38 to $41.

Analyst Upgrades

BTIG Reiterates Buy on IDEAYA Biosciences, Maintains $62 Price Target

BTIG analyst Justin Zelin reiterates IDEAYA Biosciences with a Buy and maintains $62 price target.